Lixte Biotechnology Closes Higher After Share Sale to Regain Nasdaq Compliance

Dow Jones

Jul 04, 2025

By Josh Beckerman

Lixte Biotechnology Holdings continued their upward trajectory Thursday as the pharmaceutical company said it believes it has regained compliance with Nasdaq's stockholders' equity requirement after a private placement.

Shares rose 40%, to $2.83, in the shortened regular session Thursday and were recently at $2.65 after hours. Trading volume was 63.97 million shares in the regular session, compared with a 65-day average of 818,062.

The stock closed at 71 cents on June 27, with closing prices of 91 cents and $1.18 for the next two sessions.

Lixte said after the bell Tuesday that it agreed to sell $5 million of securities, including common stock or pre-funded warrants, Series B convertible preferred stock and common warrants. On Wednesday, shares surged 71%.

Lixte previously disclosed a Nasdaq non-compliance with the $2.5 minimum stockholders' equity requirement. In a Thursday securities filing, Lixte said it believes it has stockholders' equity in excess of $2.5 million and is awaiting a compliance determination from Nasdaq.

Write to Josh Beckerman at josh.beckerman@wsj.com

(END) Dow Jones Newswires

July 03, 2025 14:53 ET (18:53 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2548382828"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2548382828\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2548382828?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-04 02:53","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2548382828","market":"sg","top_or_hot":-1,"title":"Lixte Biotechnology Closes Higher After Share Sale to Regain Nasdaq Compliance","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Josh Beckerman \n</p>\n<pre>\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/LIXT\">Lixte Biotechnology</a> Holdings continued their upward trajectory Thursday as the pharmaceutical company said it believes it has regained compliance with <a href=\"https://laohu8.com/S/NDAQ\">Nasdaq</a>'s stockholders' equity requirement after a private placement. \n</p>\n<p>\n  Shares rose 40%, to $2.83, in the shortened regular session Thursday and were recently at $2.65 after hours. Trading volume was 63.97 million shares in the regular session, compared with a 65-day average of 818,062. \n</p>\n<p>\n  The stock closed at 71 cents on June 27, with closing prices of 91 cents and $1.18 for the next two sessions. \n</p>\n<p>\n  Lixte said after the bell Tuesday that it agreed to sell $5 million of securities, including common stock or pre-funded warrants, Series B convertible preferred stock and common warrants. On Wednesday, shares surged 71%. \n</p>\n<p>\n  Lixte previously disclosed a Nasdaq non-compliance with the $2.5 minimum stockholders' equity requirement. In a Thursday securities filing, Lixte said it believes it has stockholders' equity in excess of $2.5 million and is awaiting a compliance determination from Nasdaq. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Josh Beckerman at josh.beckerman@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 03, 2025 14:53 ET (18:53 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Lixte Biotechnology Closes Higher After Share Sale to Regain Nasdaq Compliance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLixte Biotechnology Closes Higher After Share Sale to Regain Nasdaq Compliance\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-07-04 02:53</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Josh Beckerman \n</p>\n<pre>\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/LIXT\">Lixte Biotechnology</a> Holdings continued their upward trajectory Thursday as the pharmaceutical company said it believes it has regained compliance with <a href=\"https://laohu8.com/S/NDAQ\">Nasdaq</a>'s stockholders' equity requirement after a private placement. \n</p>\n<p>\n  Shares rose 40%, to $2.83, in the shortened regular session Thursday and were recently at $2.65 after hours. Trading volume was 63.97 million shares in the regular session, compared with a 65-day average of 818,062. \n</p>\n<p>\n  The stock closed at 71 cents on June 27, with closing prices of 91 cents and $1.18 for the next two sessions. \n</p>\n<p>\n  Lixte said after the bell Tuesday that it agreed to sell $5 million of securities, including common stock or pre-funded warrants, Series B convertible preferred stock and common warrants. On Wednesday, shares surged 71%. \n</p>\n<p>\n  Lixte previously disclosed a Nasdaq non-compliance with the $2.5 minimum stockholders' equity requirement. In a Thursday securities filing, Lixte said it believes it has stockholders' equity in excess of $2.5 million and is awaiting a compliance determination from Nasdaq. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Josh Beckerman at josh.beckerman@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 03, 2025 14:53 ET (18:53 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2548382828","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2548382828","pubTimestamp":1751568780,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Lixte Biotechnology Holdings continued their upward trajectory Thursday as the pharmaceutical company said it believes it has regained compliance with Nasdaq's stockholders' equity requirement after a private placement.Shares rose 40%, to $2.83, in the shortened regular session Thursday and were recently at $2.65 after hours. Trading volume was 63.97 million shares in the regular session, compared with a 65-day average of 818,062.The stock closed at 71 cents on June 27, with closing prices of 91 cents and $1.18 for the next two sessions.Lixte said after the bell Tuesday that it agreed to sell $5 million of securities, including common stock or pre-funded warrants, Series B convertible preferred stock and common warrants. On Wednesday, shares surged 71%.Lixte previously disclosed a Nasdaq non-compliance with the $2.5 minimum stockholders' equity requirement. In a Thursday securities filing, Lixte said it believes it has stockholders' equity in excess of $2.5 million and is awaiting a co","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4588":"碎股","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","BK4112":"金融交易所和数据","BK4585":"ETF&股票定投概念","NDAQ":"纳斯达克OMX交易所","BK4139":"生物科技","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","LIXT":"Lixte Biotechnology Holdings Inc.","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H",".IXIC":"NASDAQ Composite"},"translate_title":"Lixte Biotechnology在出售股票以恢复纳斯达克合规性后收盘走高","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LIXT":0.9,".IXIC":1,"NDAQ":1,"NQmain":1},"content_text":"By Josh Beckerman \n\n\n \n\n\nLixte Biotechnology Holdings continued their upward trajectory Thursday as the pharmaceutical company said it believes it has regained compliance with Nasdaq's stockholders' equity requirement after a private placement. \n\n\n  Shares rose 40%, to $2.83, in the shortened regular session Thursday and were recently at $2.65 after hours. Trading volume was 63.97 million shares in the regular session, compared with a 65-day average of 818,062. \n\n\n  The stock closed at 71 cents on June 27, with closing prices of 91 cents and $1.18 for the next two sessions. \n\n\n  Lixte said after the bell Tuesday that it agreed to sell $5 million of securities, including common stock or pre-funded warrants, Series B convertible preferred stock and common warrants. On Wednesday, shares surged 71%. \n\n\n  Lixte previously disclosed a Nasdaq non-compliance with the $2.5 minimum stockholders' equity requirement. In a Thursday securities filing, Lixte said it believes it has stockholders' equity in excess of $2.5 million and is awaiting a compliance determination from Nasdaq. \n\n\n \n\n\n  Write to Josh Beckerman at josh.beckerman@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  July 03, 2025 14:53 ET (18:53 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}